2. Gene
  3. CYP2A6 - cytochrome P450 family 2 subfamily A member 6 Gene

CYP2A6 - cytochrome P450 family 2 subfamily A member 6 Gene

  • Gene
  • Protein
  • Disease
  • Agent
Homo sapiens

Also known as CPA6; CYP2A; CYP2A3; P450PB; CYPIIA6; P450C2A

Gene ID: 1548 | Gene type: protein coding

About CYP2A6

Cytogenetic location: 19q13.2 Genomic coordinates (GRCh38): 19:40,843,541-40,850,447 (from NCBI)

This gene has 4 transcripts (splice variants), 117 orthologues, 15 paralogues and is associated with 5 phenotypes. Restricted expression toward liver (RPKM 542.0).

Summary

This gene, CYP2A6, encodes a member of the Cytochrome P450 superfamily of enzymes. The Cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of Cholesterol, Steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The Enzyme is known to hydroxylate coumarin, and also metabolizes nicotine, aflatoxin B1, nitrosamines, and some pharmaceuticals. Individuals with certain allelic variants are said to have a poor metabolizer phenotype, meaning they do not efficiently metabolize coumarin or nicotine. This gene is part of a large cluster of Cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. The gene was formerly referred to as CYP2A3; however, it has been renamed CYP2A6. [provided by RefSeq, Jul 2008]

CYP2A6 Products(1)

mRNA Protein Name
NM_000762.6 NP_000753.3 cytochrome P450 2A6 precursor

CYP2A6 Protein Structure

p450

p450: Cytochrome P450 (34 - 490)

  • 0
  • 100
  • 200
  • 300
  • 400
  • 494 a.a.
Protein Preferred Names Protein Names

cytochrome P450 2A6

1,4-cineole 2-exo-monooxygenase

Related Diseases

Diseases Alias
Tobacco Addiction

Nicotine Dependence

Tobacco Addiction, Susceptibility To

Nicotine Addiction

Tobacco Use Disorder

Smoking Habit

Nicotine Dependence, Protection Against

Nicotine Addiction, Protection From

Cigarette Habituation

Cigarette Habituation, Susceptibility To

Smoking Habit, Susceptibility To

Nicotine Dependence, Susceptibility To

Nicotine Addiction, Susceptibility To

Addiction, Tobacco, Susceptibility To

Compulsive Tobacco User Syndrome

Tobacco Dependence

Tobacco Dependence Syndrome

Cigarette Addiction

Cigarette Dependence

Smoking Addiction

Smokers Syndrome
Coumarin Resistance

Warfarin Resistance

Warfarin Sensitivity

Coumadin Sensitivity

Warfarin Response

Poor Metabolism Of Coumarin

Coumarin, Poor Metabolism Of

CMRES
Lung Cancer

Lung Carcinoma

Non-Small Cell Lung Carcinoma

Lung Cancer, Susceptibility To

Lung Cancer, Protection Against

Adenocarcinoma Of Lung, Somatic

Adenocarcinoma Of Lung, Response To Tyrosine Kinase Inhibitor In

Nonsmall Cell Lung Cancer

Lung Neoplasm

Carcinoma Of Lung

Lung Non-Small Cell Carcinoma

Non-Small Cell Lung Cancer

Nsclc

Lung Neoplasms

Malignant Neoplasm Of Lung

Alveolar Cell Carcinoma

Nonsmall Cell Lung Cancer, Somatic

Nonsmall Cell Lung Cancer, Response To Tyrosine Kinase Inhibitor In

Nonsmall Cell Lung Cancer, Susceptibility To

Lung Cancer, Somatic

Lung Cancer, Resistance To

Cancer Of Lung

Cancer Of Bronchus

Cancer Of The Lung

Lung Malignancies

Lung Malignant Tumors

Malignant Lung Tumor

Malignant Tumor Of Lung

Pulmonary Cancer

Pulmonary Carcinoma

Pulmonary Neoplasms

Respiratory Carcinoma

LNCR

Adenocarcinoma Of Lung

Neoplasm Of Lung

Cancer Lung

Carcinoma Non-Small Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Cancers

Lung Carcinomas

Cancer, Lung

Cancer, Lung, Non-Small Cell

Primary Malignant Neoplasm Of Lung

Bronchioloalveolar Adenocarcinoma
Letrozole Toxicity
Acetaminophen Metabolism
Liver Cirrhosis

Cirrhosis

Cirrhosis Of Liver

CIRRH

Cryptogenic Cirrhosis

Cirrhosis, Cryptogenic

Cirrhosis Nos
Substance Dependence
Alcoholic Liver Cirrhosis

Alcoholic Cirrhosis

Portal Cirrhosis

Alcoholic Cirrhosis Of Liver

Liver Cirrhosis, Alcoholic

Laennec'S Cirrhosis

Laennec'S Cirrhosis, Alcoholic

Alcohol Cirrhosis

Alcoholic Laennec Cirrhosis

Alcoholic Cirrhosis Nos

Etoh Cirrhosis

Alcohol Hepatic Cirrhosis

Alcohol Liver Cirrhosis

Laennec Cirrhosis
Tinea Cruris

Dermatophytosis Of Groin & Perianal Area

Dermatophytosis Of Groin And Perianal Area

Dhobie Itch

Tinea Of Perianal Region
Lung Adenoma

Adenoma Of Lung

Pulmonary Adenoma
Colorectal Cancer

Colon Cancer

Colorectal Carcinoma

Colon Carcinoma

Colorectal Cancer, Susceptibility To

Carcinoma Of Colon

CRC

Colorectal Cancer With Chromosomal Instability, Somatic

Colon Cancer, Somatic

Colon Cancer, Susceptibility To

Colonic Neoplasms

Colorectal Neoplasms

Colorectal Cancer, Somatic

Colon Cancer, Advanced, Somatic

Colonic Carcinoma

Colorectal Carcinomas

Colon Cancers

Colorectal Cancers

Cancer, Colorectal, Somatic

Cancer, Colon

Cancer, Colorectal, Susceptibility To

Colorectal Neoplasm

Colonic Neoplasm

Malignant Tumor Of Colon
Bilirubin Metabolic Disorder

Hyperbilirubinemia

Hereditary Hyperbilirubinemia

Hyperbilirubinemia, Hereditary

Hyperbilirubinaemia
Body Mass Index Quantitative Trait Locus 11

OBESITY

Obesity, Susceptibility To

Leanness, Inherited

Obesity, Susceptibility To, Bmiq11

Obesity, Mild, Early-Onset

Obesity, Association With

Obesity, Early-Onset, Susceptibility To

Obesity, Severe

Obesity, Severe, And Type Ii Diabetes

Obesity, Late-Onset

Obesity , Susceptibility To

BMIQ11

Obesity Bmiq11

Obesity, Early-Onset

Simple Obesity Nos

Excess Fat

Obesity, Not Elsewhere Classified, Body Mass Index Not Elsewhere Classified

Adiposis
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

Approval
Bioactive Molecules (4)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-17356 Fenofibrate 99.93% Yes
HY-17459 Clopidogrel hydrogen sulfate Inhibitor 99.43% Yes
HY-B1184 Mephenytoin 99.96% Unkown
HY-17459R Clopidogrel hydrogen sulfate (Standard) Inhibitor / Unkown
Clinical Phase
Bioactive Molecules (3)
Cat. No. Product Name Effect
Purity Phase
HY-129105 Clomethiazole 99.75% Phase 3
HY-12946 BI 653048 / Phase 1
HY-12946A BI 653048 phosphate / Phase 1
Pre-clinical Phase
Bioactive Molecules (66)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-N0043 Ginsenoside Rd Inhibitor 98.07% Unkown
HY-N0904 Ginsenoside C-K Inhibitor ≥98.0% Unkown
HY-W008364 Olivetol Inhibitor 99.81% Unkown
HY-N0494 Gentiopicroside Inhibitor 99.52% Unkown
HY-14362 GSK-25 Inhibitor 99.68% Unkown
HY-105124 Bufuralol Antagonist 99.17% Unkown
HY-N5132 (-)-Fenchone ≥98.0% Unkown
HY-N0598 Ginsenoside F1 Inhibitor ≥99.0% Unkown
HY-135331 N-Desmethyl-Apalutamide 99.68% Unkown
HY-N2425 Rhodiosin Inhibitor 99.36% Unkown
HY-N2260 Cephaeline dihydrochloride Inhibitor 99.84% Unkown
HY-100665 Dehydroaripiprazole Agonist 99.66% Unkown
HY-N2071 Cedrol Inhibitor ≥98.0% Unkown
HY-W011235 Norfluoxetine hydrochloride Inhibitor 99.27% Unkown
HY-W040468 2-Phenyl-2-(1-piperidinyl)propane Inhibitor 99.81% Unkown
HY-W010195 2,6-Dimethylquinoline Inhibitor 99.95% Unkown
HY-105124A Bufuralol hydrochloride Antagonist ≥99.0% Unkown
HY-133116 4-Hydroxyatomoxetine 97.04% Unkown
HY-135810A Cletoquine oxalate Inhibitor 99.76% Unkown
HY-17356R Fenofibrate (Standard) 99.91% Unkown
HY-100238 Antihistamine-1 99.45% Unkown
HY-16718 Dagrocorat 99.90% Unkown
HY-B1184S1 Mephenytoin-d5 98.06% Unkown
HY-B0352A (S)-Mirtazapine Antagonist 99.76% Unkown
HY-133116S 4-Hydroxyatomoxetine-d3 98.89% Unkown
HY-135560 Nicotelline Inhibitor 99.92% Unkown
HY-151239 ONT-993 Inhibitor 95.13% Unkown
HY-16718A Dagrocorat hydrochloride 99.85% Unkown
HY-N1483 Guanfu base A Inhibitor 98.10% Unkown
HY-N2129 N-Nornuciferine Inhibitor 99.82% Unkown
HY-N8382 Chalepensin Inhibitor ≥98.0% Unkown
HY-W754151 N-Desmethyl apalutamide-d4 99.63% Unkown
HY-100064S O-Desmethyl gefitinib-d8 Inhibitor 99.84% Unkown
HY-100064S1 O-Desmethyl gefitinib-d6 Inhibitor / Unkown
HY-100665R Dehydroaripiprazole (Standard) Agonist / Unkown
HY-100665S Dehydroaripiprazole-d8 Agonist / Unkown
HY-110134 S07662 Inhibitor / Unkown
HY-113575 Dehydroaripiprazole hydrochloride Agonist / Unkown
HY-135810 Cletoquine Inhibitor / Unkown
HY-135810S Cletoquine-d4 Inhibitor / Unkown
HY-135810S1 Cletoquine-d4-1 Inhibitor / Unkown
HY-144285 CXCR4 antagonist 4 Antagonist / Unkown
HY-144286 CXCR4 antagonist 3 Inhibitor / Unkown
HY-146177 CYP3A4 enzyme-IN-1 Inhibitor / Unkown
HY-147810 5-HT7 receptor ligand 1 / Unkown
HY-148597 FGFR-IN-10 Inhibitor / Unkown
HY-156330 HIV-IN-9 Inhibitor / Unkown
HY-17356G Fenofibrate (GMP) / Unkown
HY-17356S Fenofibrate-d6 / Unkown
HY-17356S1 Fenofibrate-d4 / Unkown
HY-17459S Clopidogrel-d3 hydrogen sulfate / Unkown
HY-18063 ML252 Inhibitor / Unkown
HY-B0352AS (S)-Mirtazapine-d3 Antagonist ≥99.0% Unkown
HY-B1184S2 Mephenytoin-d8 / Unkown
HY-N0043R Ginsenoside Rd (Standard) Inhibitor / Unkown
HY-N0904R Ginsenoside C-K (Standard) Inhibitor / Unkown
HY-N11706 β-Cedrene Inhibitor / Unkown
HY-N3090 Peucedanol Inhibitor / Unkown
HY-N6023 Thermopsoside Inhibitor / Unkown
HY-N6989 Isoglycycoumarin / Unkown
HY-RS03454 CYP2A6 Human Pre-designed siRNA Set A / Unkown
HY-RS03456 CYP2B6 Human Pre-designed siRNA Set A / Unkown
HY-RS03461 CYP2D6 Human Pre-designed siRNA Set A / Unkown
HY-134664 8α-(2-Methylacryloyloxy)-hirsutinolide-13-O-acetate Inhibitor / Unkown
HY-155456 CYP2A6-IN-1 Inhibitor / Unkown
HY-100064 O-Desmethyl gefitinib 99.40% Unkown